Tourmaline Bio(TRML) - 2024 Q3 - Quarterly Results

Exhibit 99.1 TOURMALINE Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights – On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry experts, in October 2024 – – Showcased poster presentations at the American Society of Preventive Cardiology Annual Congress in August 2024 and the 19 Annual Cardiometabolic Health Congress in October 2 ...